Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07175428 · ClinicalTrials.gov registry record · Phase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
A Phase 2 study of Atrial Fibrillation (AF), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,200
- Enrollment target
- 20
- Study locations
NCT07175428: Recruiting Phase 2 study of Atrial Fibrillation (AF), sponsored by Regeneron Pharmaceuticals.
NCT07175428 is a Phase 2 study of Atrial Fibrillation (AF) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 1,200 participants, above the 649-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (85% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07175428, a Phase 2 study of Atrial Fibrillation (AF), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)
Primary Outcome
Defined as the composite of International Society on Thrombosis and Haemostasis (ISTH) major bleeding, ISTH Clinically Relevant Non-Major (CRNM) bleeding, or minor bleeding
Conditions Studied
Interventions
- DRUG Apixaban
- DRUG REGN7508
- DRUG REGN9933
Study Locations (20)
California
- Mission Cardiovascular Research Institute - Fremont
- National Institute of California Heart and Vein Specialists - Huntington Beach
- Profound Research LLC at Southern California Heart Specialists - Pasadena
- Empire Clinical Research - Pomona
- Northbay Clinical Research Center - Santa Rosa
- Cardiology Associates Medical Group - Ventura
- Interventional Cardiology Medical Group - West Hills
Florida
- Nouvelle Clinical Research LLC - Cutler Bay
- Inpatient Research Clinic LLC - Miami Lakes
- Cardiovascular Center of Sarasota Foundation for Research and Education - Sarasota
- Clinical Site Partners, LLC DBA Flourish Research - Winter Park
Indiana
- Indiana University - Indianapolis
- Blue Coast Research Center, LLC - Indianapolis
- Franciscan Physician Network, Indiana Heart Physicians - Indianapolis
- Reid Physician Associates - Richmond
Alabama
- SEC Clinical Research - Dothan
- Eastern Shore Research Institute - Fairhope
Georgia
- Health Sciences Research Building II - Atlanta
- NSC Research, Inc - Johns Creek
Louisiana
- Monroe Research, LLC - West Monroe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2025-10-20 |
| Est. Completion | 2027-04-21 |
| Phase | Phase 2 |
What NCT07175428 shows while recruiting
NCT07175428 is an interventional study that assigns participants to a tested intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, above the 649-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (85% higher).
The record links to 1 condition, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 3 interventions - of which Apixaban is the first listed.
NCT07175428 names 20 study sites across 6 states, led by California, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT07175428 about?
NCT07175428 is a clinical study titled "Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation". This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillati...
What is the current status of trial NCT07175428?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,200 participants. The study started on 2025-10-20. Estimated completion is 2027-04-21.
What conditions does trial NCT07175428 study?
This clinical trial studies the following conditions: Atrial Fibrillation (AF).
What interventions are being tested in trial NCT07175428?
The interventions under investigation include: Apixaban (DRUG), REGN7508 (DRUG), REGN9933 (DRUG).
Who is sponsoring clinical trial NCT07175428?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07175428 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation (AF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07175428's enrollment target sits among peer trials
1,200 4th of 17 higher than 14 of 17 other Atrial Fibrillation (AF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation (AF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
ACTIVE NOT RECRUITING · Phase 2
-
Digitally Rendered Interventions And Knowledge To Limit Ethanol-Associated Atrial Fibrillation Severity
RECRUITING · NA
-
Incidence of Long-TeRm Atrial Fibrillation After Acute Illness
RECRUITING
-
Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation
RECRUITING · NA
-
Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)
RECRUITING
-
Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI